In contrast to JAK inhibitors, until now, STAT inhibitors have not been marketed due to the structural peculiarities and functional complexities of STAT, which are still in the clinical research stage and are primarily concentrated in the field of cancer (18). The gene discussed is SOAT1; the disease is cancer.